Phaseline

Companies › Dasher Neuroscience

Dasher Neuroscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YA-101–Phase 2Multiple System AtrophyJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06848231YA-101Phase 2Multiple System AtrophyNeurologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ThromBio Appello Pharmaceuticals PhenoNet Glycomine RyCarma Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.